- Home
- ICCM vs BTAI Comparison
ICCM vs BTAI Comparison
Compare ICCM & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | BTAI |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 35.6M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ICCM | BTAI |
|---|---|---|
| Price | $0.23 | $1.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $23.00 |
| AVG Volume (30 Days) | 547.4K | ★ 643.0K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $139.51 | $197.82 |
| Revenue Next Year | $75.66 | $910.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $1.01 |
| 52 Week High | $1.40 | $8.08 |
Technical Indicators
Market Signals| Indicator | ICCM | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 39.02 |
| Support Level | N/A | $1.02 |
| Resistance Level | $0.74 | $1.26 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 8.24 | 8.06 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.